1.Basic info.
 
Product Name:Octreotide Acetate
CAS No. : 83150-76-9
Purity (HPLC) : 98.0%min.
Molecular Formula : C49H66N10O10S2
Molecular Weight : 1019.28
Appearance : White powder
Single Impurity (HPLC) : 1.0%max
Amino Acid Composition : ±10% of theoretical
Peptide Content (N%) : ≥80.0%
Water Content(Karl Fischer) : ≤7.0%
Acetate Content(HPIC) : ≤12.0%
Specific Rotation (20/D) : -45.0~-50.0°(c=0.5 95%HAc)
MS (ESI) : Consistent
Mass Balance : 95.0~105.0%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8ºC preservation
Usage : octreotide acetate, as an injectable depot formulation for the treatment of growth hormone producing tumors (acromegaly and gigantism).
 
2.Product Description:

 Octreotide (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics naturalsomatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.

Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (e.g., carcinoid tumors, vasoactive intestinal peptide tumors) that are found usually in the intestines and pancreas. The symptoms occur when these tumors make too much of certain natural substances (hormones). This medication works by blocking the production of these hormones. By decreasing watery diarrhea, octreotide helps to reduce the loss of body fluids and minerals.

Octreotide is also used to treat a certain condition (acromegaly) that occurs when the body makes too much of a certain natural substance called growth hormone. Treating acromegaly helps reduce the risk of serious problems such as diabetes andheart disease. Octreotide works by decreasing the amount of growth hormone to normal levels

3.Product Applications:

 
Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinides overdose. It has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.

Octreotide has been used experimentally to treat obesity, particularly obesity caused by lesions in the hunger and satiety centers of the hypothalamus, a region of the brain central to the regulation of food intake and energy expenditure. The circuit begins with an area of the hypothalamus, the arcuate nucleus, that has outputs to the lateral hypothalamus and ventromedial hypothalamus (VMH), the brain's feeding and satiety centers, respectively.The VMH is sometimes injured by ongoing treatment for acute lymphoblastic leukemia (ALL) or surgery or radiation to treat posterior cranial fossa tumors.

Need long-term Octreotide Acetate treatment of acromegaly, such as postoperative residual tumor growth hormone to increase serum levels of growth hormone, pituitary after external beam radiotherapy has yet to reach full therapeutic serum growth hormone levels, some are not suitable for the surgical treatment and new diagnosis of growth hormone secretion adenomas in patients with preoperative treatment.